BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 15532847)

  • 1. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
    Romano F; Piacentini MG; Franciosi C; Caprotti R; De Fina S; Cesana G; Uggeri F; Conti M; Uggeri F
    Hepatogastroenterology; 2004; 51(60):1872-6. PubMed ID: 15532847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
    Romano F; Cesana G; Berselli M; Gaia Piacentini M; Caprotti R; Bovo G; Uggeri F
    J Surg Oncol; 2004 Dec; 88(4):240-7. PubMed ID: 15565596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients.
    Romano F; Cesana G; Caprotti R; Bovo G; Uggeri F; Piacentini MG; Crippa S; Uggeri F
    Hepatogastroenterology; 2006; 53(70):634-8. PubMed ID: 16995478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical surgery does not recover immunodeficiency associated with gastric cancer.
    Romano F; Caprotti R; Bravo AF; Conti M; Colombo G; Piacentini G; Uggeri F; Uggeri F
    J Exp Clin Cancer Res; 2003 Jun; 22(2):179-83. PubMed ID: 12866567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IGF-1 and IGF-1BP3 in gastric adenocarcinoma. Preliminary study.
    Franciosi CM; Piacentini MG; Conti M; Romano F; Musco F; Caprotti R; Rovelli F; Uggeri F
    Hepatogastroenterology; 2003; 50(49):297-300. PubMed ID: 12630045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis.
    Cesana GC; Romano F; Piacentini G; Scotti M; Brenna A; Bovo G; Vaghi M; Aletti G; Caprotti R; Kaufman H; Uggeri F
    Ann Surg Oncol; 2007 Apr; 14(4):1295-304. PubMed ID: 17225981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
    Lissoni P; Brivio F; Brivio O; Fumagalli L; Gramazio F; Rossi M; Emanuelli G; Alderi G; Lavorato F
    J Biol Regul Homeost Agents; 1995; 9(1):31-3. PubMed ID: 8553906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous preoperative administration of IL-2 in operable cancer patients.
    Brivio F; Lissoni P; Gilardi R; Ferrante R; Vigore L; Curzi L; Uggeri F; Nespoli A; Fumagalli L
    J Biol Regul Homeost Agents; 2000; 14(3):200-3. PubMed ID: 11037053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunodeficiency in different histotypes of radically operable gastrointestinal cancers.
    Romano F; Uggeri F; Crippa S; Di Stefano G; Scotti M; Scaini A; Caprotti R; Uggeri F
    J Exp Clin Cancer Res; 2004 Jun; 23(2):195-200. PubMed ID: 15354402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunotherapy in radical surgery of colorectal carcinoma].
    Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
    Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase IB study on prevention of surgery-induced immunodeficiency with preoperative administration of low-dose subcutaneous interleukin-2 in gastric cancer patients.
    Cerea K; Romano F; Bravo AF; Motta V; Uggeri F; Brivio F; Fumagalli LA; Uggeri F
    J Surg Oncol; 2001 Sep; 78(1):32-7. PubMed ID: 11519066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1B study of subcutaneously administered interleukin 2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer.
    Recchia F; De Filippis S; Rosselli M; Saggio G; Cesta A; Fumagalli L; Rea S
    Clin Cancer Res; 2001 May; 7(5):1251-7. PubMed ID: 11350891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum.
    Elias D; Farace F; Triebel F; Hattchouel JM; Pignon JP; Lecesne A; Rougier P; Lasser P; Duvillard P; Escudier B
    J Am Coll Surg; 1995 Oct; 181(4):303-10. PubMed ID: 7551323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial.
    Tímár J; Ladányi A; Forster-Horváth C; Lukits J; Döme B; Remenár E; Godény M; Kásler M; Bencsik B; Répássy G; Szabó G; Velich N; Suba Z; Elo J; Balatoni Z; Pócza K; Zemplén B; Chretien P; Talor E
    J Clin Oncol; 2005 May; 23(15):3421-32. PubMed ID: 15908653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative interleukin-2 immunotherapy in pancreatic cancer: preliminary results.
    Angelini C; Bovo G; Muselli P; Mussi C; Crippa S; Caprotti R; Uggeri F
    Hepatogastroenterology; 2006; 53(67):141-4. PubMed ID: 16506394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase-II randomized study of pre-operative IL-2 administration in operable NSCLC.
    Masotti A; Morandini G; Ortolani R; Fumagalli L
    Lung Cancer; 1998 Jun; 20(3):191-202. PubMed ID: 9733054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of gastric cancer surgery in elderly patients.
    Kolodziejczyk P; Kulig J; Popiela T; Sierzega M; Jedrys J; Czupryna A; Kubisz A; Szczepanik A; Klek S;
    Hepatogastroenterology; 2005; 52(66):1911-5. PubMed ID: 16334805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline.
    Brivio F; Lissoni P; Rovelli F; Nespoli A; Uggeri F; Fumagalli L; Gardani G
    Hepatogastroenterology; 2002; 49(44):385-7. PubMed ID: 11995457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.
    Mantovani G; Macciò A; Madeddu C; Mulas C; Massa E; Astara G; Ferreli L; Mudu MC; Gramignano G; Murgia V; Lusso MR; Mocci M; Cardia A; Mura L
    Oncol Rep; 2002; 9(4):887-96. PubMed ID: 12066227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current concepts in gastric cancer surgery.
    Schumacher IK; Hunsicker A; Youssef PS; Lorenz D
    Saudi Med J; 2002 Jan; 23(1):62-8. PubMed ID: 11938366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.